Immune checkpoints: A therapeutic target in triple negative breast cancer.

ABSTRACT: Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

SUBMITTER: Chawla A 

PROVIDER: S-EPMC4022604 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature